{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:00:44Z","timestamp":1787029244850,"version":"build-2736575974"},"reference-count":87,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["395357507-SFB 1371"],"award-info":[{"award-number":["395357507-SFB 1371"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005713","name":"Technical University of Munich","doi-asserted-by":"publisher","award":["Open Access Publishing Program"],"award-info":[{"award-number":["Open Access Publishing Program"]}],"id":[{"id":"10.13039\/501100005713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008751","name":"Federal Institute for Risk Assessment","doi-asserted-by":"publisher","award":["43-001"],"award-info":[{"award-number":["43-001"]}],"id":[{"id":"10.13039\/501100008751","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Despite numerous advances in personalized phage therapy, smooth logistics are challenging, particularly for multidrug-resistant Gram-negative bacterial infections requiring high numbers of specific lytic phages. We conducted this study to pave the way for efficient logistics for critically ill patients by (1) closely examining and improving a current pipeline under realistic conditions, (2) offering guidelines for each step, leading to safe and high-quality phage supplies, and (3) providing a tool to evaluate the pipeline\u2019s efficiency. Due to varying stipulations for quality and safety in different countries, we focused the pipeline on all steps up to a required phage product by a cell-free extract system. The first of three study runs included patients with respiratory bacterial infections from four intensive care units, and it revealed a cumulative time of up to 23 days. Ultimately, adjustment of specific set points of the vulnerable components of the pipeline, phage isolation, and titration increased the pipeline\u2019s efficiency by 15% and decreased the maximum required time to 13 days. We present a site-independent practical approach to establish and optimize pipelines for personalized phage delivery, the co-organization of pipeline components between different institutions, non-binding guidelines for every step, and an efficiency check for phage laboratories.<\/jats:p>","DOI":"10.3390\/ph15020186","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T05:42:33Z","timestamp":1643866953000},"page":"186","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Practical Assessment of an Interdisciplinary Bacteriophage Delivery Pipeline for Personalized Therapy of Gram-Negative Bacterial Infections"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0787-3894","authenticated-orcid":false,"given":"Silvia","family":"W\u00fcrstle","sequence":"first","affiliation":[{"name":"Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Stender","sequence":"additional","affiliation":[{"name":"Bundeswehr Institute of Microbiology, 80937 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-4358","authenticated-orcid":false,"given":"Jens Andr\u00e9","family":"Hammerl","sequence":"additional","affiliation":[{"name":"Unit Epidemiology, Zoonoses and Antimicrobial Resistances, Department Biological Safety, German Federal Institute for Risk Assessment, 10589 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Vogele","sequence":"additional","affiliation":[{"name":"Physics of Synthetic Biological Systems-E14, Physics-Department and ZNN, Technical University Munich, 85748 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Rothe","sequence":"additional","affiliation":[{"name":"Institute for Medical Microbiology, Immunology and Hygiene, School of Medicine, Technical University of Munich, 81675 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9604-3384","authenticated-orcid":false,"given":"Christian","family":"Willy","sequence":"additional","affiliation":[{"name":"Trauma & Orthopaedic Surgery, Septic & Reconstructive Surgery, Research and Treatment Centre Septic Defect Wounds, Bundeswehr (Military) Academic Hospital Berlin, 10115 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim Jakob","family":"Bugert","sequence":"additional","affiliation":[{"name":"Bundeswehr Institute of Microbiology, 80937 Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1089\/sur.2018.184","article-title":"Bacteriophages: A Therapy Concept against Multi-Drug-Resistant Bacteria","volume":"19","author":"Rohde","year":"2018","journal-title":"Surg. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/phage.2020.0014","article-title":"Bacteriophages Could Be a Potential Game Changer in the Trajectory of Coronavirus Disease (COVID-19)","volume":"1","author":"Wojewodzic","year":"2020","journal-title":"PHAGE"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1080\/22221751.2021.1902754","article-title":"Pre-optimized phage therapy on secondary Acinetobacter baumannii infection in four critical COVID-19 patients","volume":"10","author":"Wu","year":"2021","journal-title":"Emerg. Microbes Infect"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s15010-019-01319-0","article-title":"Successful adjunctive use of bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa infection in a cystic fibrosis patient","volume":"47","author":"Law","year":"2019","journal-title":"Infection"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/22221751.2020.1747950","article-title":"Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae","volume":"9","author":"Bao","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ppul.25190","article-title":"Bacteriophage therapy for infections in CF","volume":"56","author":"Chan","year":"2021","journal-title":"Pediatric Pulmonol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/cid\/ciz782","article-title":"Eradication of a Multidrug-Resistant, Carbapenemase-Producing Klebsiella pneumoniae Isolate Following Oral and Intra-rectal Therapy With a Custom Made, Lytic Bacteriophage Preparation","volume":"70","author":"Corbellino","year":"2020","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1093\/cid\/ciaa705","article-title":"Phage Therapy for Limb-threatening Prosthetic Knee Klebsiella pneumoniae Infection: Case Report and In Vitro Characterization of Anti-biofilm Activity","volume":"73","author":"Cano","year":"2021","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/phage.2020.0046","article-title":"Isolation and Characterization of Klebsiella Phages for Phage Therapy","volume":"2","author":"Townsend","year":"2021","journal-title":"PHAGE"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Abedon, S.T., Danis-Wlodarczyk, K.M., and Alves, D.R. (2021). Phage Therapy in the 21st Century: Is There Modern, Clinical Evidence of Phage-Mediated Efficacy?. Pharmaceuticals, 14.","DOI":"10.3390\/ph14111157"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1007\/s11095-014-1617-7","article-title":"Quality and safety requirements for sustainable phage therapy products","volume":"32","author":"Pirnay","year":"2015","journal-title":"Pharmaceuticals Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41596-020-0346-0","article-title":"Standardized bacteriophage purification for personalized phage therapy","volume":"15","author":"Luong","year":"2020","journal-title":"Nat. Protoc."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Paul, K., Merabishvili, M., Hazan, R., Christner, M., Herden, U., Gelman, D., Khalifa, L., Yerushalmy, O., Coppenhagen-Glazer, S., and Harbauer, T. (2021). Bacteriophage Rescue Therapy of a Vancomycin-Resistant Enterococcus faecium Infection in a One-Year-Old Child following a Third Liver Transplantation. Viruses, 13.","DOI":"10.3390\/v13091785"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.3389\/fmicb.2020.01161","article-title":"Good Manufacturing Practice (GMP) Compliance for Phage Therapy Medicinal Products","volume":"11","author":"Bretaudeau","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Abedon, S.T., Danis-Wlodarczyk, K.M., and Wozniak, D.J. (2021). Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth. Pharmaceuticals, 14.","DOI":"10.3390\/ph14101019"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S2666-5247(21)00127-0","article-title":"Clinical Phage Microbiology: A suggested framework and recommendations for the in-vitro matching steps of phage therapy","volume":"2","author":"Gelman","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Philipson, C.W., Voegtly, L.J., Lueder, M.R., Long, K.A., Rice, G.K., Frey, K.G., Biswas, B., Cer, R.Z., Hamilton, T., and Bishop-Lilly, K.A. (2018). Characterizing Phage Genomes for Therapeutic Applications. Viruses, 10.","DOI":"10.3390\/v10040188"},{"key":"ref_18","unstructured":"Moya, A., and P\u00e9rez Brocal, V. (2018). Phage on Tap: A Quick and Efficient Protocol for the Preparation of Bacteriophage Laboratory Stocks. The Human Virome: Methods and Protocols, Springer."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/978-1-4939-7395-8_18","article-title":"Bacteriophage Production in Compliance with Regulatory Requirements","volume":"1693","author":"Pirnay","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"ysy002","DOI":"10.1093\/synbio\/ysy002","article-title":"Cell-free TXTL synthesis of infectious bacteriophage T4 in a single test tube reaction","volume":"3","author":"Rustad","year":"2018","journal-title":"Synth. Biol."},{"key":"ref_21","first-page":"e56144","article-title":"Synthesis of Infectious Bacteriophages in an E. coli-based Cell-free Expression System","volume":"126","author":"Rustad","year":"2017","journal-title":"J. Vis. Exp. JoVE"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"W\u00fcrstle, S., Stender, J., Hammerl, J.A., Vogele, K., Rothe, K., Willy, C., and Bugert, J.J. (2022, January 29). Practical Assessment of an Interdisciplinary Bacteriophage Delivery Pipeline for Personalized Therapy of Gram-Negative Bacterial Infections. Available online: Https:\/\/Bookerar.Shinyapps.Io\/Pipeline\/.","DOI":"10.3390\/ph15020186"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1473-3099(20)30140-7","article-title":"A phage-based decolonisation strategy against pan-resistant enterobacterial strains","volume":"20","author":"Poirel","year":"2020","journal-title":"Lancet. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coviro.2021.11.005","article-title":"European regulatory aspects of phage therapy: Magistral phage preparations","volume":"52","author":"Verbeken","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Pirnay, J.P., Verbeken, G., Ceyssens, P.J., Huys, I., De Vos, D., Ameloot, C., and Fauconnier, A. (2018). The Magistral Phage. Viruses, 10.","DOI":"10.3390\/v10020064"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1128\/JCM.01924-13","article-title":"wzi Gene sequencing, a rapid method for determination of capsular type for Klebsiella strains","volume":"51","author":"Brisse","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1074\/jbc.M117.805689","article-title":"The outer-membrane protein TolC of Vibrio cholerae serves as a second cell-surface receptor for the VP3 phage","volume":"293","author":"Fan","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1089\/gen.40.02.13","article-title":"Phage therapy may combine efficacy and convenience: A father-son team rolls out PhageBank ATMs to help ensure that phage therapy gains currency","volume":"40","author":"LeMieux","year":"2020","journal-title":"Genet. Eng. Biotechnol. News"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rohde, C., Resch, G., Pirnay, J.P., Blasdel, B.G., Debarbieux, L., Gelman, D., G\u00f3rski, A., Hazan, R., Huys, I., and Kakabadze, E. (2018). Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains. Viruses, 10.","DOI":"10.3390\/v10040178"},{"key":"ref_31","first-page":"397","article-title":"Lysis and the interaction between free phages and infected cells","volume":"T4","author":"Abedon","year":"1994","journal-title":"Mol. Biol. Bacteriophage"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-394805-2.00001-4","article-title":"Chapter 1\u2014Phage Therapy Pharmacology: Phage Cocktails","volume":"Volume 78","author":"Laskin","year":"2012","journal-title":"Advances in Applied Microbiology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/978-1-4939-7395-8_9","article-title":"Guidelines to Compose an Ideal Bacteriophage Cocktail","volume":"1693","author":"Merabishvili","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Suh, G.A., Lodise, T.P., Tamma, P.D., Knisely, J.M., Alexander, J., Aslam, S., Barton, K.D., Bizzell, E., Totten, K.M.C., and Campbell, J. (2022). Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrob. Agents Chemother.","DOI":"10.1128\/aac.02071-21"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Abedon, S.T. (2017). Information Phage Therapy Research Should Report. Pharmaceuticals, 10.","DOI":"10.3390\/ph10020043"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"McCallin, S., Sacher, J.C., Zheng, J., and Chan, B.K. (2019). Current State of Compassionate Phage Therapy. Viruses, 11.","DOI":"10.3390\/v11040343"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-394438-2.00003-7","article-title":"Chapter 3\u2014Clinical Aspects of Phage Therapy","volume":"Volume 83","author":"Szybalski","year":"2012","journal-title":"Advances in Virus Research"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki (2013). Ethical principles for medical research involving human subjects. JAMA, 310, 2191\u20132194.","DOI":"10.1001\/jama.2013.281053"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Tanir, T., Orellana, M., Escalante, A., Moraes de Souza, C., and Koeris, M.S. (2021). Manufacturing Bacteriophages (Part 1 of 2): Cell Line Development, Upstream, and Downstream Considerations. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090934"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"594868","DOI":"10.3389\/fmicb.2020.594868","article-title":"Bacteriophage Enumeration and Detection Methods","volume":"11","author":"Gambino","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-7343-9_1","article-title":"Basic Phage Mathematics","volume":"1681","author":"Abedon","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e1220348","DOI":"10.1080\/21597081.2016.1220348","article-title":"Phage therapy dosing: The problem(s) with multiplicity of infection (MOI)","volume":"6","author":"Abedon","year":"2016","journal-title":"Bacteriophage"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-4939-7604-1_11","article-title":"Phage Therapy: Various Perspectives on How to Improve the Art","volume":"1734","author":"Abedon","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/978-1-4939-7343-9_3","article-title":"Practical Advice on the One-Step Growth Curve","volume":"1681","author":"Kropinski","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.coviro.2021.12.011","article-title":"Shopping for phages? Unpacking design rules for therapeutic phage cocktails","volume":"52","author":"Lood","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2217\/fmb.13.47","article-title":"Phage cocktails and the future of phage therapy","volume":"8","author":"Chan","year":"2013","journal-title":"Future Microbiol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hyman, P. (2019). Phages for Phage Therapy: Isolation, Characterization, and Host Range Breadth. Pharmaceuticals, 12.","DOI":"10.3390\/ph12010035"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s00705-019-04267-0","article-title":"Genomic characterization of four novel Staphylococcus myoviruses","volume":"164","author":"Oduor","year":"2019","journal-title":"Arch. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-1-4939-7343-9_9","article-title":"Sequencing, Assembling, and Finishing Complete Bacteriophage Genomes","volume":"1681","author":"Russell","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e00066-18","DOI":"10.1128\/CMR.00066-18","article-title":"Phage Therapy in the Postantibiotic Era","volume":"32","author":"Barr","year":"2019","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Howard-Jones, A.R., Iredell, J.R., and Khatami, A. (2021). Phage therapy in pediatrics: The way forward for difficult-to-treat infections?. Expert Rev. Anti-Infect. Ther., 1\u20135.","DOI":"10.1080\/14787210.2022.1990755"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s11095-010-0313-5","article-title":"The Phage Therapy Paradigm: Pr\u00eat-\u00e0-Porter or Sur-mesure?","volume":"28","author":"Pirnay","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Duyvejonck, H., Merabishvili, M., Vaneechoutte, M., de Soir, S., Wright, R., Friman, V.P., Verbeken, G., De Vos, D., Pirnay, J.P., and Van Mechelen, E. (2021). Evaluation of the Stability of Bacteriophages in Different Solutions Suitable for the Production of Magistral Preparations in Belgium. Viruses, 13.","DOI":"10.3390\/v13050865"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1007\/s00253-018-8811-1","article-title":"Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: An ambitious and also a realistic application?","volume":"102","author":"Maciejewska","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-4939-8682-8_4","article-title":"Phage on Tap: A Quick and Efficient Protocol for the Preparation of Bacteriophage Laboratory Stocks","volume":"1838","author":"Bonilla","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Liu, D., Van Belleghem, J.D., de Vries, C.R., Burgener, E., Chen, Q., Manasherob, R., Aronson, J.R., Amanatullah, D.F., Tamma, P.D., and Suh, G.A. (2021). The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies. Viruses, 13.","DOI":"10.20944\/preprints202105.0231.v1"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Moraes de Souza, C., Tanir, T., Orellana, M., Escalante, A., and Koeris, M.S. (2021). Manufacturing Bacteriophages (Part 2 of 2): Formulation, Analytics and Quality Control Considerations. Pharmaceuticals, 14.","DOI":"10.3390\/ph14090895"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cis.2017.05.014","article-title":"Formulation, stabilisation and encapsulation of bacteriophage for phage therapy","volume":"249","author":"Malik","year":"2017","journal-title":"Adv. Colloid Interface Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.addr.2018.06.018","article-title":"Use of phage therapy to treat long-standing, persistent, or chronic bacterial infections","volume":"145","author":"Abedon","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"599906","DOI":"10.3389\/fmicb.2020.599906","article-title":"A Phage Therapy Guide for Clinicians and Basic Scientists: Background and Highlighting Applications for Developing Countries","volume":"11","author":"Khalid","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.copbio.2020.10.002","article-title":"Unlocking the next generation of phage therapy: The key is in the receptors","volume":"68","author":"Barr","year":"2021","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"D\u00fczg\u00fcne\u015f, N., Sessevmez, M., and Yildirim, M. (2021). Bacteriophage Therapy of Bacterial Infections: The Rediscovered Frontier. Pharmaceuticals, 14.","DOI":"10.3390\/ph14010034"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"113864","DOI":"10.1016\/j.addr.2021.113864","article-title":"Formulation strategies for bacteriophages to target intracellular bacterial pathogens","volume":"176","author":"Yan","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_64","first-page":"81","article-title":"Phage Therapy: The Pharmacology of Antibacterial Viruses","volume":"40","author":"Abedon","year":"2021","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e00012-19","DOI":"10.1128\/MMBR.00012-19","article-title":"Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies","volume":"83","author":"Abedon","year":"2019","journal-title":"Microbiol. Mol. Biol. Rev. MMBR"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Azeredo, J., and Sillankorva, S. (2018). In Vivo Bacteriophage Biodistribution. Bacteriophage Therapy: From Lab to Clinical Practice, Springer.","DOI":"10.1007\/978-1-4939-7395-8"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Onsea, J., Uyttebroek, S., Chen, B., Wagemans, J., Lood, C., Van Gerven, L., Spriet, I., Devolder, D., Debaveye, Y., and Depypere, M. (2021). Bacteriophage Therapy for Difficult-to-Treat Infections: The Implementation of a Multidisciplinary Phage Task Force (The PHAGEFORCE Study Protocol). Viruses, 13.","DOI":"10.3390\/v13081543"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e00954-17","DOI":"10.1128\/AAC.00954-17","article-title":"Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/genetics\/28.6.491","article-title":"Mutations of Bacteria from Virus Sensitivity to Virus Resistance","volume":"28","author":"Luria","year":"1943","journal-title":"Genetics"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1743-422X-10-100","article-title":"Characterising the biology of novel lytic bacteriophages infecting multidrug resistant Klebsiella pneumoniae","volume":"10","author":"Kassner","year":"2013","journal-title":"Virol. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1473-3099(20)30330-3","article-title":"Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: A randomised, placebo-controlled, double-blind clinical trial","volume":"21","author":"Leitner","year":"2021","journal-title":"Lancet. Infect. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","article-title":"Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1\/2 trial","volume":"19","author":"Jault","year":"2019","journal-title":"Lancet. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"J\u00e4ckel, C., Hammerl, J.A., Reetz, J., Kropinski, A.M., and Hertwig, S. (2015). Campylobacter group II phage CP21 is the prototype of a new subgroup revealing a distinct modular genome organization and host specificity. BMC Genom., 16.","DOI":"10.1186\/s12864-015-1837-1"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.3201\/eid2608.201246","article-title":"US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2","volume":"26","author":"Lu","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"ref_75","unstructured":"(2021, October 08). Available online: https:\/\/blast.ncbi.nlm.nih.gov\/Blast.cgi."},{"key":"ref_76","unstructured":"(2021, October 08). Available online: https:\/\/www.ncbi.nlm.nih.gov\/."},{"key":"ref_77","unstructured":"(2021, October 08). Available online: https:\/\/gitlab.com\/bfr_bioinformatics\/AQUAMIS\/."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: An ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_79","unstructured":"(2021, October 08). Available online: https:\/\/github.com\/tseemann\/shovill."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"i142","DOI":"10.1093\/bioinformatics\/bty266","article-title":"Versatile genome assembly evaluation with QUAST-LG","volume":"34","author":"Mikheenko","year":"2018","journal-title":"Bioinformatics"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13059-016-0997-x","article-title":"Mash: Fast genome and metagenome distance estimation using MinHash","volume":"17","author":"Ondov","year":"2016","journal-title":"Genome Biol."},{"key":"ref_82","unstructured":"(2021, October 08). Available online: https:\/\/patricbrc.org\/."},{"key":"ref_83","unstructured":"(2021, October 08). Available online: https:\/\/github.com\/tseemann\/abricate."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Feldgarden, M., Brover, V., Haft, D.H., Prasad, A.B., Slotta, D.J., Tolstoy, I., Tyson, G.H., Zhao, S., Hsu, C.H., and McDermott, P.F. (2019). Validating the AMRFinder Tool and Resistance Gene Database by Using Antimicrobial Resistance Genotype-Phenotype Correlations in a Collection of Isolates. Antimicrob. Agents Chemother., e00483-19.","DOI":"10.1128\/AAC.00483-19"},{"key":"ref_85","unstructured":"(2021, October 08). Available online: http:\/\/www.mgc.ac.cn\/VFs\/main.htm."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Sun, Z.Z., Hayes, C.A., Shin, J., Caschera, F., Murra, R.M., and Noireaux, V. (2013). Protocols for implementing an Escherichia coli based TX-TL cell-free expression system for synthetic biology. J. Vis. Exp., e50762.","DOI":"10.3791\/50762-v"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nature Methods"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/2\/186\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:13:01Z","timestamp":1760134381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/15\/2\/186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":87,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["ph15020186"],"URL":"https:\/\/doi.org\/10.3390\/ph15020186","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]}}}